In a research report released today, Maxim analyst Jason McCarthy reiterated a Buy rating on shares of Inovio Pharmaceuticals Inc (NASDAQ:INO) and raised the price …
In a research report issued Monday, Maxim Group analyst Jason McCarthy reiterated a Buy rating on shares of Kite Pharma Inc (NASDAQ:KITE) with a price …
Maxim’s healthcare analyst Jason McCarthy weighed in with some commentary on Juno Therapeutics Inc (NASDAQ:JUNO), after the company announced that FDA has cleared its investigational new drug application for …
Maxim Group analyst Jason McCarthy initiated coverage on Kite Pharma Inc (NASDAQ:KITE) with a Buy rating and a price target of $87, which represents …
In a research report released today, Maxim Group analyst Jason McCarthy initiated coverage on shares of Juno Therapeutics Inc (NASDAQ:JUNO) with a Buy rating and a …
Maxim Group analyst Jason McCarthy weighed in today with a few insights on bluebird bio Inc (NASDAQ:BLUE), after the company made amendments on its …
In a research report issued today, Maxim Group analyst Jason Mccarthy maintained a Buy rating on bluebird bio Inc (NASDAQ:BLUE) with a price …
